Profil
Ken Evans currently works as a Director at Stem Cell Bra.
Postes actifs de Ken Evans
| Sociétés | Poste | Début |
|---|---|---|
Stem Cell Bra
 Stem Cell Bra Apparel/FootwearConsumer Non-Durables Stem Cell Bra is an American company that is currently in the pre-clinical testing stage of developing a bra that uses stem cells from a woman's own fat tissue and bone marrow to possibly increase breast size by one cup over a period of 12 weeks. The stem cell bra has shown promising results in a pilot feasibility clinical study conducted in Spain in 2021, with 1/3 of the enrollees experiencing a one cup size increase, 1/3 experiencing a 10% increase, and 1/3 experiencing no change. The company has gathered safety data on 15 sheep and cows with excellent results, showing an increase in breast fullness volume ranging from 20 to 30% and true new breast tissue formation. The company has over 150 USPTO patent and patent pending claims on bioelectric regeneration methods and devices. However, the company cautions that the product is only available in countries where clinical studies have been approved by regulatory authorities and is not yet proven safe or effective in statistically significant controlled clinical studies. The company was founded by Howard J. Leonhardt, who has been the CEO since incorporation. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Stem Cell Bra
Stem Cell Bra Apparel/FootwearConsumer Non-Durables Stem Cell Bra is an American company that is currently in the pre-clinical testing stage of developing a bra that uses stem cells from a woman's own fat tissue and bone marrow to possibly increase breast size by one cup over a period of 12 weeks. The stem cell bra has shown promising results in a pilot feasibility clinical study conducted in Spain in 2021, with 1/3 of the enrollees experiencing a one cup size increase, 1/3 experiencing a 10% increase, and 1/3 experiencing no change. The company has gathered safety data on 15 sheep and cows with excellent results, showing an increase in breast fullness volume ranging from 20 to 30% and true new breast tissue formation. The company has over 150 USPTO patent and patent pending claims on bioelectric regeneration methods and devices. However, the company cautions that the product is only available in countries where clinical studies have been approved by regulatory authorities and is not yet proven safe or effective in statistically significant controlled clinical studies. The company was founded by Howard J. Leonhardt, who has been the CEO since incorporation. | Consumer Non-Durables |
